Short answer
MBX Biosciences, Inc. (MBX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$22M
- +53.3% YoY · −11.4% QoQ
- EPS (diluted)
- −$0.63
- +95.9% YoY · −6.8% QoQ
Source: XBRL data from the MBX Biosciences, Inc. (MBX) Q3 2025 10-Q on SEC EDGAR. USD.
MBX Biosciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY; no products approved or product sales
- Net loss $21.6M vs $18.1M YoY; operating loss $23.9M vs $19.6M
- Canvuparatide R&D $10.1M vs $6.0M, strongest program investment
- MBX 4291 R&D $2.7M vs $5.5M; imapextide $0.6M vs $2.1M
- Cash, equivalents and marketable securities $391.7M vs $262.1M; funding expected into 2029
Risk Factors
- New tax-law risk triggered by OBBBA, signed July 4, 2025, changing R&D deduction and amortization treatment
- Regulatory risk from Loper Bright, increasing challenges to FDA regulations and regulatory uncertainty
- Healthcare pricing risk from Executive Orders 14273 and 14297 targeting drug-price negotiation and most-favored-nation pricing
- Operational risk from government shutdowns delaying FDA reviews and regulatory submissions
- Liquidity risk from potential shutdown-related limits on public-market access and future capital raising
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MBX Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.